Oric Pharmaceuticals (ORIC) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Key program updates and clinical strategy

• Focus on prostate, lung, and breast cancer with two clinical-stage programs: rinzimetostat (PRC2 inhibitor) and enosertinib (EGFR inhibitor).

• Phase III study for rinzimetostat in prostate cancer planned to start in the first half of the year.

• Enosertinib targets both EGFR exon 20 and PAK mutations, with significant CNS activity and further updates expected in the second half of the year.

• Early clinical data for rinzimetostat show promising PSA responses and a favorable safety profile compared to competitors.

• Multiple upcoming data milestones for rinzimetostat, including a Q1 update and a larger program update in the second half of the year.

Differentiation and competitive landscape

• Rinzimetostat is an allosteric PRC2 inhibitor with improved solubility, longer half-life, and better bioavailability than other EZH2 inhibitors.

• Early clinical results indicate lower rates of GI and hematological toxicities compared to competitors.

• Enosertinib demonstrates best-in-class CNS activity, especially in patients with untreated or active brain metastases.

• The company benchmarks its data against Pfizer’s mevrometostat, aiming for at least comparable efficacy and superior safety.

• Ongoing evaluation of combination strategies and monotherapy options for enosertinib, with dose optimization favoring 80 mg for monotherapy.

Market opportunity and unmet needs

• Prostate cancer represents a large and growing market, with ARPi inhibitors generating over $11 billion in sales last year.

• Significant unmet need exists for therapies that extend radiographic PFS and improve durability beyond current AR switching and chemotherapy.

• Rinzimetostat is positioned as an oral therapy to be added to standard of care, aiming to reverse or prevent resistance to ARPi inhibitors.

• Enosertinib addresses the high prevalence of CNS metastases in lung cancer, a key differentiator in the targeted therapy space.

• Potential expansion into earlier lines of therapy and other tumor types, including combinations with KRAS inhibitors in lung and colorectal cancer.